In addition to their capacity to differentiate, BM stromal cells (BMSC) have immunosuppressive qualities that make them strong candidates for use in cell therapy against human autoimmune diseases. We studied the immunoregulatory activities of BMSC on experimental autoimmune myasthenia gravis (EAMG) in vitro and in vivo. Intravenous administration of syngenic BMSC to EAMG-model rats on the day of their second immunization was effective in ameliorating the pathological features of the disease. In vitro, the proliferative ability of T cells or B cells from EAMG rats was inhibited when they were cocultured with BMSC at proper ratios. This inhibitory effect was at least partially dependent on the secretion of IDO. We also determined that the development of EAMG is accompanied by an imbalance among the Th1, Th2, Th17, and Treg cell subsets, and that this can be corrected by the administration of BMSC, which leads to an increase of Th2 (IL-4) and Treg (Foxp3) cells, and a reduction of Th1 (IFN-c) and Th17 (IL-17) cells, through an IDO-dependent mechanism. These results provide further insights into the pathogenesis of MG, EAMG, and other immune-mediated diseases, and support a potential role for BMSC in their treatment.Key words: BM stromal cells . Experimental autoimmune myasthenia gravis . IDO . Th17Supporting Information available online Introduction BM stromal cells (BMSC, also called bone mesenchymal stem cells) are present at low frequency (1/10 4 -1/10 5 ) [1] in the adult BM of many species. They provide a scaffold for hematopoiesis and hematopoietic-cell homeostasis [2] and, under the appropriate conditions, are capable of giving rise to cells of all three germ layers, including osteoblasts, adipocytes, chondrocytes[1], skeletal myocytes [3], and neurons [4]. Their ability to generate multiple mesenchymal lineages makes them a promising candidate for use in strategies directed toward tissue engineering, repair of damaged tissues, and gene therapy [1,3,4]. BMSC have more recently been shown to have the ability to modulate many T-cell [5,6], B-cell [7], NK, and dendritic-cell [8,9] functions, suggesting that they might also for the therapy of immune-mediated disorders. When human MSC are administered in vivo, they can assist hematopoietic engraftment while hampering graft-versus-host disease [2,6,8,10]. Systemic administration of BMSC in mice suffering from EAE, a disease model of multiple sclerosis that is mediated by self-reactive T cells
800results in highly effective disease amelioration associated with a profound suppression of effector T cells and the induction of peripheral tolerance [11]. BMSC may also inhibit the maturation and function of dendritic cells [9,11], suggesting that activated T cells are not the only targets of BMSC. It has been further demonstrated that human MSC can significantly affect the proliferation, differentiation, and chemotactic behavior of normal mature B cells [7]. Though the mechanisms mediating such effects are still not fully understood, it is likely that both cell-tocell c...